Search Clinical Trials in the EU

6-12 months

Visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

21-40 of 397 trials

Nipocalimab for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to 17 with generalized myasthenia gravis who are not getting enough benefit from their current therapy. The trial will help us learn about its safety and effectiveness.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteNeurologyPediatrics

Wilms Tumor: Metronomic Chemotherapy Study

We are evaluating a new chemotherapy regimen for children and teenagers with relapsed or refractory Wilms tumor. The study aims to assess safety, effectiveness, and quality of life during treatment.

Wilms Tumor6-12 monthsEfficacy phase (II)No Placebo Standard MedicinesOncologyPediatrics

Alopecia Areata: Baricitinib for Children

We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.

Alopecia Areata6-12 monthsConfirmation phase (III)16-20 visits Standard MedicinesDermatologyPediatrics

Deucravacitinib for Inflammatory Skin Conditions

We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.

Epidermolysis BullosaCongenital Ichthyosis6-12 monthsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesDermatology

ADHD Treatment: Dexamfetamine Formulations

We are studying two types of dexamfetamine sulfate in adults with ADHD to see if they are more effective than a placebo. The trial will also evaluate the safety of these medications.

Attention Deficit Hyperactivity Disorder (ADHD)6-12 monthsConfirmation phase (III)11-15 visits Standard MedicinesNeurologyPsychiatry

Eptinezumab for Migraines in Children and Adolescents

We are studying the long-term safety of eptinezumab in children and teens aged 6 to 17 who experience chronic or episodic migraines. This research aims to ensure the medication is safe for young patients.

Migraine6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteNeurologyPediatrics

Idiopathic Pulmonary Fibrosis: Axatilimab Study

We are testing a new medication, axatilimab, for people with idiopathic pulmonary fibrosis to see if it improves lung function and overall quality of life compared to a placebo.

Idiopathic Pulmonary Fibrosis6-12 monthsEfficacy phase (II)11-15 visits Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Filgotinib for Rare Immune Diseases

We are studying how filgotinib may improve quality of life and disease activity in patients with rare conditions like Behçet's disease, idiopathic inflammatory myopathy, and IgG4-related disease.

DermatomyositisAntisynthetase SyndromeIgG4-Related Disease6-12 monthsEfficacy phase (II)No Placebo Standard MedicinesInfectious DiseasesRheumatology

Clostridioides difficile Infection: VE303 Treatment Study

We are testing a new treatment, VE303, to see if it helps prevent recurrent Clostridioides difficile infections in people who have had this infection before. The study will also evaluate safety and quality of life for participants.

Clostridioides difficile Infection6-12 monthsConfirmation phase (III)Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInfectious Diseases

Flu Vaccine Study for Adults 65 and Older

We are testing a new adjuvanted flu vaccine to see if it works as well as a standard flu vaccine in preventing influenza in older adults. The study will also evaluate safety and immune response to the vaccine.

Influenza6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard MedicinesInfectious Diseases

Crohn's Disease: Multi-Donor Fecal Microbiota Transfer Study

We are investigating whether multi-donor fecal microbiota transfer can help maintain remission in children and adults with Crohn's disease after dietary treatment. The study will assess safety, feasibility, and quality of life for participants.

Crohn's Disease6-12 monthsSafety phase (I)Efficacy phase (II)Investigational MedicinesGastroenterologyPediatrics

Follicular Lymphoma: Odronextamab vs. Rituximab

We are studying whether odronextamab combined with lenalidomide is safer and more effective than rituximab combined with lenalidomide for adults with relapsed or refractory follicular lymphoma and marginal zone lymphoma.

Marginal Zone LymphomaFollicular Lymphoma6-12 monthsConfirmation phase (III)11-15 visits No Placebo Standard Medicines Partially RemoteHematologyOncology

Chronic Hypoparathyroidism: Eneboparatide (AZP-3601)

We are studying a new medication to see if it helps people with chronic hypoparathyroidism manage their calcium levels and improve their physical symptoms. This trial compares the new treatment to a placebo to assess its effectiveness.

Hypoparathyroidism6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Partially RemoteEndocrinology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteOncology

Type 2 Diabetes: BCAA Oxidation Study

We are investigating whether boosting branched-chain amino acid oxidation can lower blood sugar levels in people with type 2 diabetes. The study also examines effects on insulin sensitivity, heart health, and cognitive function.

Type 2 Diabetes6-12 monthsMonitoring phase (IV)6-10 visits No Placebo Standard Medicines Cost ReimbursementDiabetologyEndocrinology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Pembrolizumab for Progressive Multifocal Leukoencephalopathy in Immunocompromised Patients

We are studying whether Pembrolizumab can help reduce the JCV viral load in the cerebrospinal fluid of immunocompromised patients with PML. This trial aims to understand its effects on neurological health and overall survival.

Progressive Multifocal Leukoencephalopathy (PML)6-12 monthsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesInfectious DiseasesNeurology

Advanced Non-Small Cell Lung Cancer: Zipalertinib with Chemotherapy

We are studying whether adding zipalertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have a specific genetic mutation. This trial compares the effects of the combination treatment to chemotherapy alone.

Non-Small Cell Lung Cancer6-12 monthsConfirmation phase (III)16-20 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncologyPulmonology

Advanced Cholangiocarcinoma: Futibatinib Study

We are studying the effects of futibatinib in patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. The goal is to see if it helps improve their condition and to understand its safety.

Cholangiocarcinoma6-12 monthsEfficacy phase (II)No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Periodontitis: Vitamin D3 Supplementation Study

We are testing whether vitamin D3 can improve gum health in people with periodontitis and low vitamin D levels. This study will help us understand its effects alongside standard gum treatments.

Periodontitis6-12 monthsMonitoring phase (IV)≤5 visits Standard MedicinesInternal MedicineOtolaryngology

Search Clinical Trials in the European Union